Early studies suggested that circulating plasma OT concentrations is relatively stable in the basal state 4 but recent observations using deconvolution analysis have confirmed that a pulsatile 
pattern of OT secretion exists in men at rest and that OT concentrations correlate with indices of socio-emotional functioning. 5 In keeping with the progressive rise in OT levels during pregnancy, OT concentrations are stimulated in response to oestrogen administration 6, 7 ; however, they may not vary significantly according to phase of the menstrual cycle. 6, 7 Some , 4, 8 but not all, 9 studies report a diurnal variation in secretion, with concentrations at their lowest in the afternoon and evening, and rising steeply after midnight. 4 It is unclear if ageing has an effect on secretion: although one study showed no effect of age on either the pattern of release or absolute OT concentrations, 4 only a small number of subjects were included and further studies are needed. In women, physiological stimuli such as breastfeeding and labour induce a pulsatile release of OT into the peripheral circulation whereas in men, peripheral OT concentrations have been shown to rise during sexual arousal. 10 Peripherally-administered OT has a very short half-life in human plasma (2-8 minutes) 11 and displays poor permeability across the blood-brain barrier, with <1% of peripherally-administered OT appearing in the cerebrospinal fluid (CSF). 2, 12 These pharmacokinetic properties present a challenge when considering its therapeutic potential as a neuroactive drug. OT exerts its effects through binding to the G protein-coupled OT receptor. Although only one canonical receptor for OT is thought to exist in mammals, arginine-vasopressin (AVP), which shares seven of nine amino acids, is thought to have the following three: the V1a, V1b and V2 receptors. These evolutionarily ancient receptors exhibit a high degree of structural homology, hence it is not surprising that considerable crosstalk between OT and AVP and their receptors can occur. 13 This has implications not only for our understanding of the roles of these peptides in a variety of physiological processes but also for drug design with respect to receptor selectivity.
| PHYS I OLOG I C AL EFFEC TS
Oxytocin has a well-established role in the regulation of labour, in keeping with its derivation from the Greek for "quick birth". It stimulates cervical ripening and dilatation, is uterotonic, and facilitates uterine contraction and clotting in the postpartum period. OT also stimulates breast myoepithelial cells to help initiate the let-down reflex in lactation (Figure 2 ).
More recently, its role in the regulation of a number of other physiological processes has become appreciated, notably in relation to food intake and metabolism. 14 Knockout mice deficient in either F I G U R E 1 Oxytocin synthesis and secretion [Colour figure can be viewed at wileyonlinelibrary.com]
F I G U R E 2 Actions of oxytocin OT or the OT receptor are obese and glucose intolerant, 15, 16 whilst OT administration reduces food intake, increases energy expenditure and improves glucose homoeostasis. [17] [18] [19] The effects on food intake are rapid and sustained, 17, 18 with obese rats appearing to be more sensitive to the effects of OT on weight loss than lean animals. 20 In humans, studies have shown that peripheral OT levels are elevated in obesity 21 and the metabolic syndrome, 22 and correlate with BMI and fat mass. 21, 22 Conversely, OT concentrations may be lowered in the presence of overt diabetes. [23] [24] [25] Acutely, intranasal OT administration reduces caloric intake 26, 27 with a preferential reduction in fat consumption 26 ; as in animals, these effects are more pronounced in obesity. 27 These actions may be mediated at least in part by modification of hedonic as well as homoeostatic pathways. 14, 17, 28 Single dose experiments have also shown an increase in fat oxidation, 26 and beneficial effects on glucose homoeostasis and insulin sensitivity. [26] [27] [28] [29] Conversely, the benefits seen in animal models with respect to increased energy expenditure have not yet been confirmed in humans. 26, 28 An important caveat is that the OT dose used in these studies may be considered supra-physiological (24 IU), exceeding both the estimated OT store in the posterior pituitary (14 IU) and the intravenous doses employed in labour (1-30 mIU/min). At these doses, some of the effects of OT may be mediated via actions at AVP receptors. 30 Furthermore, studies to date have been largely limited to men; hence, it is unclear whether these metabolic benefits are also apparent in women. In contrast to acute administration, only a few studies have examined the effects of sustained OT administration on body weight and metabolic outcomes, although a number of clinical trials are ongoing. In a randomized, placebo-controlled study of intranasal OT (24 IU four times daily) in subjects with overweight/obesity, OT reduced body weight by a mean of 9 kg after 8 weeks, albeit that only nine participants received active treatment. 19 Conversely, no effects on weight were seen in two randomized, placebo-controlled trials of intranasal OT in Prader-Willi syndrome, 31, 32 although the total daily OT exposure was lower in these studies than in Zhang et al. 19 Oxytocin receptors are expressed in the adrenal and anterior pituitary glands; hence, it is not surprising that OT administration has an effect on the hypothalamic-pituitary-adrenal (HPA) axis. Studies have shown consistently that OT, whether administered intravenously or intranasally, reduces ACTH and cortisol secretion under both basal and stress conditions. [33] [34] [35] Intravenous OT has also been shown to block corticotrophin-induced ACTH release, 36 although no reports of hypoadrenalism have emerged to date. In animals, OT has been shown to modulate sodium balance but recent data in humans showed no influence of dietary sodium intake on circulating OT levels. 37 Nevertheless, given its ability to bind to vasopressin receptors including the V2 subtype, hyponatraemia may develop in response to treatment, at least in high doses such as those used in labour. 38 
| PSYCHOLOG IC AL EFFEC TS
Early studies in the 1990 s demonstrated profound effects of OT on sexual and maternal behaviour in animals, since replicated in human studies which confirm an important role of OT in normal parenting. 39 OT is now known to exert a wide range of effects on human social and emotional behaviour (Figure 2) , from influencing the way in which individuals respond to social exclusion, 40, 41 to moral dilemmas 42 and how they allocate resources. 43 Moreover, OT regulates the way in which individuals process emotional information 44 and, in turn, facilitates the identification of emotions 45 ; as such OT may be implicated in many mental health disorders. Altered OT concentrations or responses are evident in patients with postnatal depression, 46 schizophrenia, 47 autism spectrum disorder (ASD) 48 and attention-deficit hyperactivity disorder. 49 Given OT's pivotal role in adaptive social behaviour, studies have investigated the potential therapeutic role of OT administration in improving characteristic behavioural symptoms associated with these disorders. For example, Tauber et al 50 found that infants with Prader-Willi Syndrome who received intranasal OT showed improved sucking, increased acylated ghrelin production and improved parent-infant interaction. To date, the disorder that has received the most attention with regard to the therapeutic potential of OT is ASD, with a systematic review finding significant benefits with respect to emotion recognition and eye gaze. 48 Whilst clinical trials into the effects of OT in individuals with ASD are ongoing, larger and longerterm studies are needed to confirm these findings and those in other mental health disorders.
| MORB IDIT Y, MORTALIT Y AND QUALIT Y OF LIFE IN HYP OPITU ITARIS M: AN UNME T NEED
Hypopituitarism, referring to reduced secretion of pituitary hormones, affects roughly 45 people per 100 000 of the general population. Pituitary adenomas, extrasellar tumours and treatments for these tumours (surgery, radiotherapy) account for the majority of cases in adults, although infective, inflammatory, infiltrative, traumatic, vascular and congenital disease may also occur. This diverse range of aetiologies contributes to differences in morbidity and treatment outcomes. Notably, hypothalamic insult, whether arising directly from tumours (such as craniopharyngioma) or treatments for such tumours (especially surgery), is a major cause of morbidity, 51, 52 not least due to obesity and its metabolic sequelae, arising as a result of disruption to appetite-regulating centres.
Although the introduction of glucocorticoid, thyroid, sex steroid and growth hormone replacement therapy has transformed outcomes in hypopituitarism, a number of studies have shown that the mortality and morbidity experience of patients still does not reach population norms. Meta-analyses have consistently demonstrated an excess mortality in hypopituitarism despite apparent optimal replacement therapy, 53, 54 driven largely by deaths related to vascular disease. The risks of premature death appear greater in young-onset disease and in women. 54 Of note, the standardized mortality ratio in patients with craniopharyngioma is particularly high. Several studies have demonstrated impaired quality of life (QOL) in patients with hypopituitarism, whether measured by generic or disease-specific tools. 56, 57 QOL is particularly impaired in craniopharyngioma, 58, 59 with the most common domains affected including emotional and social functioning. 58, 59 Additional treatments are therefore needed to address this burden and to improve patient experience.
| OX Y TO CIN IN HYP OPITU ITARIS M
In the light of the impaired QOL, neuropsychological deficits and obesity frequently evident in patients with craniopharyngioma, and OT's synthesis in the hypothalamus, studies have begun to address whether OT deficiency is present in hypopituitarism, and if so whether this is accompanied by psychological deficits that might be amenable to therapeutic intervention (Table 1) . A 2016 case report highlighted an improvement in pro-social behaviour in response to nasal OT in a boy following surgical treatment of a craniopharyngioma. 60 Daubenbüchel et al 61 
| D IAG NOS TI C CHALLENG E S
Whilst these observations of a potential neuropsychological and metabolic benefit of OT in hypopituitarism are encouraging, a number of challenges need to be addressed before OT can be considered for adoption into clinical practice. Firstly, reliable measurement of plasma OT concentration is not straightforward. 67 Falsely elevated OT levels are often observed with modern radioimmunoassays due to interference from other immunoreactive products, 68 a problem common also to enzyme-linked immunosorbent assays (ELISAs).
Sample extraction (by solid phase or solvent) is a procedure designed to eliminate the effect of potentially interfering products, reduce matrix effects and concentrate the analyte from the sample before analysis. Whilst extraction removes some of these interfering substances, ELISAs may still detect OT degradation products, whose biological activity is unknown. Moreover, the need for an extraction The optimal method by which this can be confirmed reproducibly needs to be established, whilst studies have already suggested that the presence of central diabetes insipidus is not a reliable enough surrogate. 63 
| THER APEUTIC CHALLENG E S
A number of therapeutic challenges also need to be overcome before OT can be considered as a viable treatment option in hypopituitarism.
These include its short half-life, optimal mode of administration and the safety profile of chronic administration. OT is currently administered as an intravenous preparation to induce or augment labour, and used intramuscularly or intravenously in the prevention and treatment of postpartum haemorrhage. Neither of these modes of delivery are viable as a long-term treatment option, not least because of the very short half-life of OT. 11 Intranasal OT is an unlicensed but commercially available preparation which in supra-physiological doses appears to cross the blood-brain barrier. 71 This suggests that intranasal OT might exert its actions, at least in part, through central as well as peripheral pathways. However, the typical dosing frequency of six sprays four times daily (24 IU) is inconvenient. Furthermore, it is unclear whether the observation made in mice of greater efficacy with respect to weight loss in response to continuous as opposed to bolus OT delivery 72 carries the same physiological importance in humans. Despite these limitations, intranasal OT has been used widely in human research studies with largely reassuring safety data to date, at least in the acute setting. In the 1960 s-1970 s, intranasal OT was used clinically as an alternative to intravenous OT in the induction and maintenance of labour. A study of over 1800 women treated in pregnancy showed a low rate of adverse events. 73 There are fewer safety data with respect to chronic administration, although a recent systematic review of adverse events following long-term application (>5 weeks) in patients with ASD gave further reassurance. 74 The most common adverse events were nasal discomfort, tiredness, irritability, diarrhoea and skin irritation but the frequency of these did not differ from placebo. Chronic intranasal OT administration has also been shown to be safe in other patient groups. 19 
| CON CLUS IONS
Whilst a number of studies have suggested that hypopituitarism may be associated with OT deficiency, and that OT administration has the potential to improve neuropsychological outcomes, a num- 
